If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
Revenue from operations climbed 13% to Rs. 886.87 crore
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The decision marks a key step in the centralized EU review process
Kheruka has played a key role in transforming Borosil into a diversified, international consumer-focused enterprise
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
